Trials / Recruiting
RecruitingNCT07260669
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- Sponsor
- Gesynta Pharma AB · Industry
- Sex
- Female
- Age
- 18 Years – 44 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vipoglanstat | Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period. |
| DRUG | Placebo | Participants will receive matching placebo capsules orally for approximately 4 menstrual cycles during the treatment period. |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2025-12-03
- Last updated
- 2026-04-17
Locations
41 sites across 7 countries: Bulgaria, Czechia, Hungary, Italy, Poland, Romania, United Kingdom
Source: ClinicalTrials.gov record NCT07260669. Inclusion in this directory is not an endorsement.